S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
NASDAQ:RETA

Reata Pharmaceuticals - RETA Stock Forecast, Price & News

$49.50
+2.95 (+6.34%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$45.81
$50.00
50-Day Range
$33.91
$49.50
52-Week Range
$18.47
$50.00
Volume
1.39 million shs
Average Volume
680,154 shs
Market Capitalization
$1.81 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$66.67

Reata Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
34.7% Upside
$66.67 Price Target
Short Interest
Bearish
29.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.77mentions of Reata Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($8.38) to ($8.09) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

280th out of 1,030 stocks

Pharmaceutical Preparations Industry

131st out of 502 stocks

RETA stock logo

About Reata Pharmaceuticals (NASDAQ:RETA) Stock

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Sudhof, Jonathan M. Graff, and J. Warren Huff in 2002 and is headquartered in Irving, TX.

Receive RETA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RETA Stock News Headlines

Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Reata Pharmaceuticals
Reata Pharmaceuticals (NASDAQ: RETA)
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Why Reata Pharmaceuticals Stock Is Soaring Today
Why Is Reata Pharmaceuticals (RETA) Stock Up 15% Today?
Nasdaq Tumbles Over 200 Points; Crude Oil Falls Sharply
Reata Pharma Spikes 15%
RETA Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals Inc
2RETA : Reata Pharmaceuticals Whale Trades Spotted
See More Headlines
Receive RETA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RETA Company Calendar

Last Earnings
11/08/2022
Today
2/02/2023
Next Earnings (Estimated)
2/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RETA
Fax
N/A
Employees
346
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$66.67
High Stock Price Forecast
$115.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+34.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-297,390,000.00
Net Margins
-9,897.91%
Pretax Margin
-9,890.03%

Debt

Sales & Book Value

Annual Sales
$11.49 million
Book Value
$5.11 per share

Miscellaneous

Free Float
26,127,000
Market Cap
$1.81 billion
Optionable
Optionable
Beta
1.25

Social Links


Key Executives

  • J. Warren Huff
    Chairman & Chief Executive Officer
  • Manmeet Singh Soni
    President, Chief Operating & Financial Officer
  • W. Christian Wigley
    Chief Scientific Officer & Senior Vice President
  • Edmund Doherty
    Vice President-Medical Affairs
  • Samina Khan
    Chief Medical Officer & Senior Vice President













RETA Stock - Frequently Asked Questions

Should I buy or sell Reata Pharmaceuticals stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RETA shares.
View RETA analyst ratings
or view top-rated stocks.

What is Reata Pharmaceuticals' stock price forecast for 2023?

5 brokers have issued 12-month target prices for Reata Pharmaceuticals' stock. Their RETA share price forecasts range from $40.00 to $115.00. On average, they predict the company's stock price to reach $66.67 in the next twelve months. This suggests a possible upside of 34.7% from the stock's current price.
View analysts price targets for RETA
or view top-rated stocks among Wall Street analysts.

How have RETA shares performed in 2023?

Reata Pharmaceuticals' stock was trading at $37.99 at the beginning of the year. Since then, RETA shares have increased by 30.3% and is now trading at $49.50.
View the best growth stocks for 2023 here
.

When is Reata Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our RETA earnings forecast
.

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) released its earnings results on Tuesday, November, 8th. The company reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.35) by $0.19. The business earned $0.54 million during the quarter, compared to the consensus estimate of $1.43 million. Reata Pharmaceuticals had a negative trailing twelve-month return on equity of 322.32% and a negative net margin of 9,897.91%.

What is Warren Huff's approval rating as Reata Pharmaceuticals' CEO?

10 employees have rated Reata Pharmaceuticals Chief Executive Officer Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among the company's employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Reata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).

When did Reata Pharmaceuticals IPO?

(RETA) raised $60 million in an initial public offering (IPO) on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.

What is Reata Pharmaceuticals' stock symbol?

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

Who are Reata Pharmaceuticals' major shareholders?

Reata Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.16%), Woodstock Corp (0.04%), Bank of Hawaii (0.03%), HighMark Wealth Management LLC (0.03%), ProShare Advisors LLC (0.02%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Insiders that own company stock include Colin John Meyer, Elaine Castellanos, James Warren Huff and Michael D Wortley.
View institutional ownership trends
.

How do I buy shares of Reata Pharmaceuticals?

Shares of RETA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Reata Pharmaceuticals' stock price today?

One share of RETA stock can currently be purchased for approximately $49.50.

How much money does Reata Pharmaceuticals make?

Reata Pharmaceuticals (NASDAQ:RETA) has a market capitalization of $1.81 billion and generates $11.49 million in revenue each year. The company earns $-297,390,000.00 in net income (profit) each year or ($8.56) on an earnings per share basis.

How many employees does Reata Pharmaceuticals have?

The company employs 346 workers across the globe.

How can I contact Reata Pharmaceuticals?

Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The official website for the company is www.reatapharma.com. The company can be reached via phone at (972) 865-2219 or via email at ir@reatapharma.com.

This page (NASDAQ:RETA) was last updated on 2/3/2023 by MarketBeat.com Staff